Literature DB >> 22425961

Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.

Sau Wai Hung1, Hardik R Mody, Rajgopal Govindarajan.   

Abstract

Clinical refractoriness to nucleoside analogs (e.g., gemcitabine, capecitabine) is a major scientific problem and is one of the main reasons underlying the extremely poor prognostic state of pancreatic cancer. The drugs' effects are suboptimal partly due to cellular mechanisms limiting their transport, activation, and overall efficacy. Nonetheless, novel therapeutic approaches are presently under study to circumvent nucleoside analog resistance in pancreatic cancer. With these new approaches come additional challenges to be addressed. This review describes the determinants of chemoresistance in the gemcitabine cytotoxicity pathways, provides an overview of investigational approaches for overcoming chemoresistance, and discusses new challenges presented. Understanding the future directions of the field may assist in the successful development of novel treatment strategies for enhancing chemotherapeutic efficacy in pancreatic cancer. Published by Elsevier Ireland Ltd.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22425961      PMCID： PMC3569094          DOI： 10.1016/j.canlet.2012.03.007

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  155 in total

1.  Combinatorial drug conjugation enables nanoparticle dual-drug delivery.

Authors:  Santosh Aryal; Che-Ming Jack Hu; Liangfang Zhang
Journal:  Small       Date:  2010-07-05       Impact factor: 13.281

2.  The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells.

Authors:  Susanne Gahr; Matthias Ocker; Marion Ganslmayer; Steffen Zopf; Kinya Okamoto; Andrea Hartl; Sandra Leitner; Eckhart G Hahn; Christoph Herold
Journal:  Int J Oncol       Date:  2007-09       Impact factor: 5.650

3.  Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.

Authors:  Stijn L W Koolen; Petronella O Witteveen; Robert S Jansen; Marlies H G Langenberg; Roelien H Kronemeijer; Annemarie Nol; Ignacio Garcia-Ribas; Sophie Callies; Karim A Benhadji; Christopher A Slapak; Jos H Beijnen; Emile E Voest; Jan H M Schellens
Journal:  Clin Cancer Res       Date:  2011-07-13       Impact factor: 12.531

4.  Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

Authors:  Elisa Giovannetti; Mario Del Tacca; Valentina Mey; Niccola Funel; Sara Nannizzi; Sergio Ricci; Cinzia Orlandini; Ugo Boggi; Daniela Campani; Marco Del Chiaro; Mauro Iannopollo; Generoso Bevilacqua; Franco Mosca; Romano Danesi
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

5.  ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells.

Authors:  Wolfgang Hagmann; Ralf Jesnowski; Ralf Faissner; Changqing Guo; J Matthias Löhr
Journal:  Pancreatology       Date:  2008-12-13       Impact factor: 3.996

6.  Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.

Authors:  V Heinemann; Y Z Xu; S Chubb; A Sen; L W Hertel; G B Grindey; W Plunkett
Journal:  Cancer Res       Date:  1992-02-01       Impact factor: 12.701

7.  Troxacitabine prodrugs for pancreatic cancer.

Authors:  A D Adema; M Radi; J Daft; J Narayanasamy; E K Hoebe; L E Alexander; C K Chu; G J Peters
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2007       Impact factor: 1.381

8.  Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics.

Authors:  José L Arias; L Harivardhan Reddy; Mohammad Othman; Brigitte Gillet; Didier Desmaële; Fatima Zouhiri; Franco Dosio; Ruxandra Gref; Patrick Couvreur
Journal:  ACS Nano       Date:  2011-01-28       Impact factor: 15.881

9.  pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs.

Authors:  Timothy K Williams; Christina L Costantino; Nikolai A Bildzukewicz; Nathan G Richards; David W Rittenhouse; Lisa Einstein; Joseph A Cozzitorto; Judith C Keen; Abhijit Dasgupta; Myriam Gorospe; Gregory E Gonye; Charles J Yeo; Agnieszka K Witkiewicz; Jonathan R Brody
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

10.  Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.

Authors:  Y Nakano; S Tanno; K Koizumi; T Nishikawa; K Nakamura; M Minoguchi; T Izawa; Y Mizukami; T Okumura; Y Kohgo
Journal:  Br J Cancer       Date:  2007-01-16       Impact factor: 7.640
View more
  36 in total

1.  Clobenpropit enhances anti-tumor effect of gemcitabine in pancreatic cancer.

Authors:  Woo Hyun Paik; Ji Kon Ryu; Kyoung-Sin Jeong; Jin Myung Park; Byeong Jun Song; Sang Hyub Lee; Yong-Tae Kim; Yong Bum Yoon
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 2.  A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments.

Authors:  Kenta Masui; Beatrice Gini; Jill Wykosky; Ciro Zanca; Paul S Mischel; Frank B Furnari; Webster K Cavenee
Journal:  Carcinogenesis       Date:  2013-03-01       Impact factor: 4.944

Review 3.  Molecular Imaging of Membrane Transporters' Activity in Cancer: a Picture is Worth a Thousand Tubes.

Authors:  Aniv Mann; Inessa Semenenko; Michal Meir; Sara Eyal
Journal:  AAPS J       Date:  2015-03-31       Impact factor: 4.009

4.  Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer.

Authors:  Gang-Gang Mu; Ling-Li Zhang; Hong-Yan Li; Yan Liao; Hong-Gang Yu
Journal:  Dig Dis Sci       Date:  2014-10-26       Impact factor: 3.199

5.  E2F2 enhances the chemoresistance of pancreatic cancer to gemcitabine by regulating the cell cycle and upregulating the expression of RRM2.

Authors:  Qianfan Liu; Chunzhuo Song; Junjun Li; Meng Liu; Liyue Fu; Jiuliang Jiang; Zhirui Zeng; Haitao Zhu
Journal:  Med Oncol       Date:  2022-06-18       Impact factor: 3.064

6.  Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy.

Authors:  Yuan Zhang; William Y Kim; Leaf Huang
Journal:  Biomaterials       Date:  2013-02-04       Impact factor: 12.479

7.  Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells.

Authors:  Xu Zhu; Robert M Straubinger; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-08-08       Impact factor: 2.745

8.  Polymeric Micelles of PEG-PLA Copolymer as a Carrier for Salinomycin Against Gemcitabine-Resistant Pancreatic Cancer.

Authors:  Zahra Daman; Hamed Montazeri; Masoumeh Azizi; Faegheh Rezaie; Seyed Nasser Ostad; Mohsen Amini; Kambiz Gilani
Journal:  Pharm Res       Date:  2015-07-31       Impact factor: 4.200

9.  Norleual, a hepatocyte growth factor and macrophage stimulating protein dual antagonist, increases pancreatic cancer sensitivity to gemcitabine.

Authors:  Kevin J Church; Brett R Vanderwerff; Rachelle R Riggers; Beatriz Mateo-Victoriano; Matthew Fagnan; Phillip H Harris; Jewel C LeValley; Joseph W Harding
Journal:  Anticancer Drugs       Date:  2018-04       Impact factor: 2.248

10.  Heat shock protein 47 confers chemoresistance on pancreatic cancer cells by interacting with calreticulin and IRE1α.

Authors:  Akihiro Yoneda; Kenjiro Minomi; Yasuaki Tamura
Journal:  Cancer Sci       Date:  2021-06-09       Impact factor: 6.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.